INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

Estimated average burden
OMB Number:			3235-0104
hours per response:			0.5

1. Name and Address of Reporting Person^*

Joyce Roby

(Last)

(First)

(Middle)

C/O BIOAFFINITY TECHNOLOGIES, INC.,

22211 WEST INTERSTATE 10, SUITE 1206

(Street)

SAN ANTONIO,

78257

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/18/2023

3. Issuer Name and Ticker or Trading Symbol
bioAffinity Technologies, Inc. [ BIAF ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	583,130⁽¹⁾	I	The Joyce Living Trust⁽²⁾

**Table II - Derivative Securities Beneficially Owned**
**(e.g., puts, calls, warrants, options, convertible securities)**
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Warrant	07/20/2022	07/20/2027	Common Stock	5,714	5.25	I	The Joyce Living Trust⁽²⁾
Warrant	11/22/2021	11/22/2026	Common Stock	14,285	5.25	I	The Joyce Living Trust⁽²⁾

Explanation of Responses:

1. Includes: (i) 18,158 shares of common stock issued to The Joyce Living Trust on September 6, 2022 and (ii) 564,972 shares of restricted common stock that were granted on September 18, 2023, in connection with an Asset Purchase Agreement between bioAffinity Technologies, Inc. and Village Oaks Pathology Services, P.A., of which Dr. Joyce is the principal and owner.

2. Dr. Joyce is the co-Trustee of The Joyce Living Trust (the "Trust"), together with his wife, Joyce M. Joyce, each of whom may act unilaterally with regard to voting and disposition power with respect to the shares owned by the Trust. Dr. Joyce and Mrs. Joyce are the beneficiaries of the Trust.

Remarks:

Exhibit List - Exhibit 24.1: Power of Attorney (Roby Joyce)

	/s/ Roby Joyce, M.D.	09/26/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.